Trial Profile

Virological and Immunological Assessment in HIV Positive Participants on 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir/lamivudine (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms 2DR; Rumba

Most Recent Events

26 Feb 2024 Planned primary completion date changed from 31 May 2023 to 30 Jun 2026.
02 May 2023 Planned End Date changed from 30 Apr 2025 to 30 Apr 2027.
02 May 2023 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com